Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients

Serum levels of interleukin-12 heterodimer (IL-12p70) and its homodimeric subunit (IL-12p40) were analyzed by enzyme-linked immunosorbent assay in 18 patients with primary progressive multiple sclerosis (MS) during 3 months before and 3 months under treatment with interferon-beta-1b (IFNβ-1b, Betafe...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience letters 2002-06, Vol.326 (2), p.125-128
Main Authors: Bahner, Dirk, Klucke, Christine, Kitze, Bernd, Elitok, Ercan, Bogumil, Timon, Dressel, Alexander, Tumani, Hayrettin, Weber, Frank, Poser, Sigrid, Bitsch, Andreas
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - therapeutic use
Adult
Biological and medical sciences
Cytokines
Female
Humans
Interferon beta-1a
Interferon beta-1b
Interferon-beta - therapeutic use
Interleukin-12
Interleukin-12 - blood
Interleukin-12 Subunit p40
Male
Medical sciences
Middle Aged
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Multiple Sclerosis, Chronic Progressive - blood
Multiple Sclerosis, Chronic Progressive - drug therapy
Neurology
Primary progressive multiple sclerosis
Protein Subunits
Reference Values
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Serum levels of interleukin-12 heterodimer (IL-12p70) and its homodimeric subunit (IL-12p40) were analyzed by enzyme-linked immunosorbent assay in 18 patients with primary progressive multiple sclerosis (MS) during 3 months before and 3 months under treatment with interferon-beta-1b (IFNβ-1b, Betaferon ™, eight million units (MIU) every other day subcutaneously). Median IL-12p40 levels in MS patients before treatment (66.5 and 63.9 pg/ml) were not elevated compared to 18 healthy controls. IL-12p40 significantly increased during treatment ( P
ISSN:0304-3940
1872-7972
DOI:10.1016/S0304-3940(02)00311-7